Insider Selling: Gilead Sciences EVP Sells 90,000 Shares of Stock (GILD)
Gilead Sciences (NASDAQ:GILD) EVP Norbert W. Bischofberger unloaded 90,000 shares of the stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $74.23, for a total transaction of $6,680,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of research firms have recently commented on GILD. Analysts at TheStreet reiterated a “positive” rating on shares of Gilead Sciences in a research note to investors on Wednesday. Separately, analysts at Nomura initiated coverage on shares of Gilead Sciences in a research note to investors on Wednesday, January 8th. They set a “buy” rating on the stock. Finally, analysts at UBS AG reiterated a “buy” rating on shares of Gilead Sciences in a research note to investors on Monday, January 6th. They now have a $102.00 price target on the stock, up previously from $80.00. Two research analysts have rated the stock with a hold rating and twenty-four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $79.76.
Gilead Sciences (NASDAQ:GILD) traded up 3.27% on Thursday, hitting $77.69. 16,920,800 shares of the company’s stock traded hands. Gilead Sciences has a 52-week low of $38.27 and a 52-week high of $76.11. The stock has a 50-day moving average of $73.66 and a 200-day moving average of $65.38. The company has a market cap of $119.1 billion and a price-to-earnings ratio of 41.40.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.04. The company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the previous year, the company posted $1.00 earnings per share. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $2.00 earnings per share for the current fiscal year.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.